EntryPoint Capital LLC Purchases New Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• EntryPoint Capital LLC acquired 40,528 shares of BioCryst Pharmaceuticals valued at approximately $304,000, contributing to a strong interest from institutional investors as they own 85.88% of the stock.
• Analysts have positively adjusted their target prices for BioCryst Pharmaceuticals, with estimates ranging from $11.00 to $18.00, indicating strong market confidence in the company.
• BioCryst reported a significant revenue increase of 49.5% in the last quarter, with an earnings per share of $0.15 that surpassed analysts' expectations.

EntryPoint Capital LLC purchased a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 40,528 shares of the biotechnology company's stock, valued at approximately $304,000.

Several other hedge funds also recently made changes to their positions in BCRX. Nuveen LLC bought a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth approximately $10,677,000. Jupiter Asset Management Ltd. grew its stake in shares of BioCryst Pharmaceuticals by 82.4% in the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock valued at $16,117,000 after buying an additional 971,040 shares in the last quarter. Balyasny Asset Management L.P. bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $3,983,000. Woodline Partners LP bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at $3,385,000. Finally, Caligan Partners LP grew its stake in shares of BioCryst Pharmaceuticals by 16.0% in the fourth quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company's stock valued at $22,529,000 after buying an additional 412,347 shares in the last quarter. 85.88% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on BCRX shares. Wedbush raised their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, June 30th. Bank of America raised their price target on BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a report on Tuesday, July 1st. Cantor Fitzgerald began coverage on BioCryst Pharmaceuticals in a report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $17.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, August 4th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $16.70.

Insider Buying and Selling

In related news, Director Theresa Heggie sold 70,000 shares of the business's stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares of the company's stock, valued at $556,145.52. The trade was a 51.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Stock Down 2.0%

Shares of BCRX traded down $0.17 during midday trading on Monday, reaching $8.39. 2,502,948 shares of the stock were exchanged, compared to its average volume of 3,348,017. BioCryst Pharmaceuticals, Inc. has a twelve month low of $6.01 and a twelve month high of $11.31. The company has a market cap of $1.76 billion, a P/E ratio of -46.61, a PEG ratio of 1.94 and a beta of 1.10. The stock's 50 day simple moving average is $8.79 and its 200 day simple moving average is $8.79.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million for the quarter, compared to analyst estimates of $149.59 million. During the same period in the prior year, the business posted ($0.06) EPS. The firm's quarterly revenue was up 49.5% compared to the same quarter last year. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.